Accuray Incorporated (ARAY) Receives Analyst Rating

Accuray Incorporated (ARAY) : 4 analysts are covering Accuray Incorporated (ARAY) and their average rating on the stock is 1.5, which is read as a Strong Buy. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Accuray Incorporated (ARAY) : The most positive equity analysts on Accuray Incorporated (ARAY) expects the shares to touch $12, whereas, the least positive believes that the stock will trade at $8 in the short term. The company is covered by 4 Wall Street Brokerage Firms. The average price target for shares are $9.75 with an expected fluctuation of $2.06 from the mean.


Accuray Incorporated (NASDAQ:ARAY): The stock opened in the green at $5.49 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $5.495 and a low of $5.43 for the day. The stock did not find buyers even at the lows and closed at $5.46 recording a loss of -0.36%. 530,101 shares exchanged hands during the trading day. The stock had closed at $5.48 in the previous days trading.

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.